Molecular diagnostics are better than older diagnostic tests; however, they are very expensive. We have developed a DASL Rapid™ technology and conducted 3 projects ( government grants $440,000) and developed prototype tests with high performance levels. We expect to raise seed financing of $1.5 million to enable regulatory approval of our first test products. We expect to reach $15 million revenue in 4 yrs and profitability in 5 yrs.